$JNJ: Johnson & Johnson Reports Erleada Reduced Recurrence or Death Risk by

$JNJ

$JNJ – Johnson & Johnson Reports Erleada Reduced Recurrence or Death Risk by 62% in Prostate Cancer Study

2026-10-24 12:59:34 UTC · TELEGRAM · All $JNJ

?? Positive AI Sentiment (+4.5 / 10)

Perioperative Erleada reduced risk of recurrence or death by 62% vs surgery alone in high-risk prostate cancer.
Data supports potential label expansion for established oncology franchise.
Positive clinical catalyst for J&J pharmaceutical division.